Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs

[1]  R A O'REILLY,et al.  STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN. , 1963, The Journal of clinical investigation.

[2]  L. Aarons,et al.  An in vitro study of drug displacement interactions: warfarin‐salicylate and warfarin‐phenylbutazone , 1979, The Journal of pharmacy and pharmacology.

[3]  S Oie,et al.  Effect of altered plasma protein binding on apparent volume of distribution. , 1979, Journal of pharmaceutical sciences.

[4]  P. Kroboth,et al.  Pharmacokinetics of the Newer Benzodiazepines , 1989, Clinical pharmacokinetics.

[5]  E. Mini,et al.  Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). , 1989, Clinical pharmacokinetics.

[6]  D. Bateman,et al.  The effect of pharmacological modification of gastric emptying and mouth‐to‐caecum transit time on the absorption of sugar probe marker molecules of intestinal permeability in normal man , 1990, European journal of clinical investigation.

[7]  C M Metzler,et al.  Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time , 1992, Clinical pharmacology and therapeutics.

[8]  E. Chan,et al.  Disposition of warfarin enantiomers and metabolites in patients during multiple dosing with rac-warfarin. , 1994, British journal of clinical pharmacology.

[9]  D. Shen,et al.  Oral first‐pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A‐mediated metabolism , 1996, Clinical pharmacology and therapeutics.

[10]  K. Turteltaub,et al.  Accelerator mass spectrometry as a bioanalytical tool for nutritional research. , 1997, Advances in experimental medicine and biology.

[11]  R C Garner,et al.  Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[12]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[13]  W. Jusko,et al.  Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. , 2003, Journal of pharmaceutical sciences.

[14]  Bengt Långström,et al.  Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development , 2003, European Journal of Clinical Pharmacology.

[15]  R D Combes,et al.  Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  R. Colin Garner,et al.  Big physics, small doses: the use of AMS and PET in human microdosing of development drugs , 2003, Nature Reviews Drug Discovery.

[17]  Innovation OR Stagnation.  Challenge and Opportunity on the Critical Path to New Medical Products , 2004 .

[18]  R. C. Garner,et al.  Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry , 2004, Analytical and bioanalytical chemistry.

[19]  A. Somogyi,et al.  Evaluation of the Intestinal Absorption of Erythromycin in Man: Absolute Bioavailability and Comparison with Enteric Coated Erythromycin , 2004, Pharmaceutical Research.

[20]  A. Telenti,et al.  Oral administration of a low dose of midazolam (75 μg) as an in vivo probe for CYP3A activity , 2004, European Journal of Clinical Pharmacology.

[21]  Martin R. Schneider,et al.  Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer. , 2004, Journal of the National Cancer Institute.

[22]  M. P. Baker,et al.  EVALUATION OF MICRODOSING STRATEGIES FOR STUDIES IN PRECLINICAL DRUG DEVELOPMENT: DEMONSTRATION OF LINEAR PHARMACOKINETICS IN DOGS OF A NUCLEOSIDE ANALOG OVER A 50-FOLD DOSE RANGE , 2004, Drug Metabolism and Disposition.

[23]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[24]  Toshinori Yamamoto,et al.  POSSIBLE INVOLVEMENT OF ORGANIC ANION TRANSPORTER 2 ON THE INTERACTION OF THEOPHYLLINE WITH ERYTHROMYCIN IN THE HUMAN LIVER , 2005, Drug Metabolism and Disposition.

[25]  D. Effeney,et al.  Concurrent intravenous administration of a labeled tracer to determine the oral bioavailability of a drug exhibiting Michaelis-Menten metabolism , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[26]  Malcolm Rowland,et al.  Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat. , 2005, Journal of pharmaceutical sciences.